Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea82 enrolled

Overview

The purpose of this study is to determine efficacy of rituximab, gemcitabine, oxaliplatin and dexametasone (R-GemOx) chemotherapy schedule.

The purpose of this study is to determine efficacy (overall response rate (ORR) and complete response) tolerance and toxicity of rituximab, gemcitabine, oxaliplatin and dexametasone (R-GemOx) chemotherapy schedule.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Aggressive Lymphoma Diffuse Large B-cell Lymphoma Mantle Cell Lymphoma

Interventions

Rituximab, Gemcitabine, Oxaliplatin, DexametasoneDRUG

until progression or unacceptable toxicity develops, 8 cicles max Rituximab: 375 mg/m2, IV, day 1. Gemcitabine: 1000 mg/m2, IV, day 2. Oxaliplatin: 100 mg/m2, IV, day 2. Dexametasone: 20 mg/day, days 1-3, oral.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age ≥ 18 years. 2. DLBCL and MCL diagnosed patients in primary resistance or relapsed not eligible for intensification chemotherapy followed by Autologous stem cell transplantation (ASCT) for age, comorbidity or previous ASCT. 3. Any IPI or ECOG, capable of understanding the nature of the trial. 4. Writtern Informed Consent. Exclusion Criteria: 1. Nursing pregnant or lactation period women, or fertile age adults not using effective contraceptive method. 2. CNS lymphoma patients. 3. Patients with severa renal (creatinine\> 2,5 UNL) or hepatic (Bilirrubin or ALT/AST\> 2,5 UNL) impairement not provided by the same disease 4. HIV positive patients. 5. Serious psychiatric diseases patients that could interfere with their skill to understand the study (including alcoholism or drug addiction). 6. Murine proteins or any other component of the medicines of the study hypersensitivity patients. 7. Patients who have received more than 2 therapeutic previous lines. (for previous ASCT patients, induction and conditioning for the TAPH treatment is considered a single line therapy).

Locations (28)

Hospital Germans Trias i Pujol

Badalona, Barcelona, Spain

Outcomes

Primary Outcomes

The primary endpoint is to evaluate Overall response rate (ORR)

The primary endpoint is to evaluate the number of patients with complete remission, unconfirmed complete remission and partial response according to International Workshop to Standardize Response Criteria for NHL, of R-GEMOX combination administered every 14 days

Time frame: 3 years and 2 months

Secondary Outcomes

Safety of Gemcitabine in combination with Rituximab, Oxaliplatin and Dexametasone (R-GemOx) in DLBCL and Mantle cell lymphoma. (GELTAMO-RGemOx)

To asses the number of Participants with Adverse Events (serious and non serious) and classification of those adverse events. Evaluate if the balance efficacy / toxicity allows the possibility of further interventions to prolong progression-free survival and overall survival

Time frame: 3 years and 2 months

To identify clinical response predictive factors

To asses if different age, sex, IPI, ECOG, stage of cancer, dissease location and time to relapse have some influence in response.

Time frame: 3 years 2 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.